Laekna Limited
Clinical trials sponsored by Laekna Limited, explained in plain language.
-
New hope for women with aggressive ovarian cancer
Disease control CompletedThis study tested whether adding a new drug called afuresertib to standard chemotherapy (paclitaxel) works better for women with ovarian cancer that has stopped responding to platinum-based drugs. About 150 participants were randomly assigned to receive either the combination or …
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for tough cancers: testing a Triple-Threat treatment
Disease control CompletedThis study tested a new three-drug combination (afuresertib, sintilimab, and chemotherapy) for people with advanced solid tumors that had stopped responding to prior immunotherapy. The goal was to find a safe, effective dose and see if this combination could help control cancer g…
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
First test of new drug in healthy women seeks safety data
Knowledge-focused CompletedThis early-stage study aimed to check the safety of a new drug called LAE102 in healthy postmenopausal women. Researchers gave single, increasing doses to 32 participants and closely monitored for any side effects. The main goal was to see how the body handles the drug and determ…
Phase: PHASE1 • Sponsor: Laekna Limited • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC